Human health and medicine

BetTeRTED study

BetTeRTED (NCT02316691), B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease, a terminated University of Pittsburgh observational cohort study started January 2016, 2 participants enrolled, no results posted.

Betty R. Ferrell

Betty R. Ferrell is an American nurse scientist who directs nursing research at City of Hope in California and leads the ELNEC palliative care training program.

Betz cell

Betz cell, giant pyramidal neuron (Riesenpyramide) of layer Vb of the primary motor cortex, described by Volodymyr Betz in 1874; largest cortical neurons, projecting via the corticospinal tract, monosynaptic to spinal motoneurons in primates, absent in rodents, and implicated in ALS.

BEVAC

BEVAC is a recombinant DNA hepatitis B vaccine by Biological E. Limited, India, WHO-prequalified 16 January 2025; 10 µg HBsAg per 0.5 mL paediatric dose, non-inferior to GeneVac-B in a phase IV trial.

Bevacizumab

Bevacizumab (Avastin) is a humanized anti-VEGF-A monoclonal antibody, the first approved angiogenesis-inhibiting cancer drug (FDA 2004), used across colorectal, lung, and other cancers and widely off-label in ophthalmology, with several approved biosimilars.

Bevacizumab and erlotinib combination therapy

Bevacizumab and erlotinib combination therapy, also called erlotinib and bevacizumab, is a two-drug regimen for advanced EGFR-mutated non-squamous lung cancer that prolongs progression-free survival but not overall survival.

Bevacizumab and temozolomide regimen

The bevacizumab and temozolomide regimen is a combination drug treatment pairing bevacizumab, an anti-VEGF antibody, with temozolomide, an oral alkylating chemotherapy, used mainly in glioblastoma.

Bevacizumab gamma

Bevacizumab gamma (bevacizumab-vikg, Lytenava, ONS-5010) is an ophthalmic formulation of the anti-VEGF monoclonal antibody bevacizumab, approved in the EU, UK, and US for intravitreal treatment of wet age-related macular degeneration.

Bevacizumab monotherapy

Bevacizumab monotherapy is the use of the monoclonal antibody bevacizumab alone, without chemotherapy, to block tumor blood vessel growth; its only approved single-agent use is recurrent glioblastoma in adults.

Bevacizumab/carboplatin regimen

The bevacizumab/carboplatin regimen is a combination chemotherapy regimen pairing the antibody bevacizumab with carboplatin, used mainly as first-line treatment of advanced non-squamous non-small cell lung cancer.

Bevacizumab/cetuximab regimen

The bevacizumab/cetuximab regimen is a combination of two monoclonal antibodies studied for metastatic colorectal cancer; trials showed worse survival and more toxicity, so it was never approved.

Bevacizumab/irinotecan regimen

The bevacizumab/irinotecan regimen combines bevacizumab, an antibody that starves tumors of blood supply, with irinotecan, a topoisomerase inhibitor, given intravenously every two weeks, mainly for recurrent glioblastoma.

Bevacizumab/paclitaxel regimen

The bevacizumab/paclitaxel regimen combines the anti-VEGF monoclonal antibody bevacizumab with the taxane chemotherapy paclitaxel, used to treat recurrent or metastatic cervical cancer and ovarian cancer, first approved in 2014.

Bevasiranib

Bevasiranib (Cand5), an siRNA against VEGF-A mRNA from Acuity Pharmaceuticals and OPKO Health, was the first siRNA in clinical trials and first RNAi drug in Phase III for wet AMD; its COBALT trial was terminated in 2009 for poor efficacy.

Bevenopran

Bevenopran (ADL-5945, CB-5945) is an oral peripheral μ-opioid receptor antagonist developed for opioid-induced constipation; it reached Phase 3 trials under Adolor and Cubist but was discontinued in 2013 and never approved.

Beverlee Myers

Beverlee A. Myers was an American public health leader who directed the California Department of Health Services from 1978 to 1983 and was elected to the National Academy of Medicine in 1985.

Bevifibatide citrate (formerly batifiban)

Bevifibatide citrate (formerly batifiban, 贝塔宁/BETAGRIN) is a cyclic peptide GPIIb/IIIa and αvβ3 dual-target antiplatelet drug approved in China in June 2024 for ACS patients undergoing PCI, with Phase III composite endpoint HR 0.57.

Bevonescein

Bevonescein (ALM-488), an Alume Biosciences peptide-fluorescein conjugate, binds nerve extracellular matrix for intraoperative nerve visualization; completed Phase 1 and Phase 3 head and neck surgery trials, NDA planned 2026.

Bewintinib

Bewintinib (OB-756, formerly Bangruitini), sold as Bangruishun, is an oral selective JAK2 inhibitor approved by China's NMPA in April 2026 for first-line treatment of intermediate-2 or high-risk myelofibrosis in adults.

Bexagliflozin

Bexagliflozin (Brenzavvy; Bexacat in cats) is an SGLT2 inhibitor approved by the FDA on January 20, 2023, dosed 20 mg daily as adjunct to diet and exercise for adult type 2 diabetes, notable for low cost and no cardiovascular outcomes trial.

Oct 15, 2026

Bezafibrate

Bezafibrate is a fibrate-class lipid-lowering drug, available in Europe since 1977 under trade names including Bezalip, used as an adjunct to diet when statins are contraindicated.

Bezisterim

Bezisterim (NE3107, HE3286, Triolex) is an oral, blood-brain barrier-permeable anti-inflammatory, insulin-sensitizing androstenetriol analogue developed by BioVie for Alzheimer's disease, Parkinson's disease, and long COVID neurological symptoms.

Bezlotoxumab

Bezlotoxumab (Zinplava, MK-6072), Merck's fully human monoclonal antibody against C. difficile toxin B, FDA-approved 2016; single 10 mg/kg IV dose, 19-day half-life, cuts CDI recurrence about 10 percentage points in MODIFY I/II.

Bezoar

Bezoar: an indigestible mass (phytobezoar, trichobezoar, diospyrobezoar) in the gastrointestinal tract, once prized as an antidote; now treated by Coca-Cola dissolution, endoscopy, or surgery.

Bezold–Jarisch reflex

Bezold–Jarisch reflex (BJR): cardioinhibitory reflex from left ventricular inferoposterior receptors via vagal C fibers causing bradycardia, vasodilation, hypotension; key in spinal anesthesia asystole, vasovagal syncope, inferior MI.

Oct 20, 2026

BFY trial

Baby's First Years (BFY) trial, NCT03593356, a US randomized controlled trial giving 1,000 low-income mothers $333 or $20 monthly unconditional cash gifts; found infant EEG changes at age 1 but null development outcomes at age 4.

BGB-43395 (CDK4 inhibitor)

BGB-43395 is an investigational oral CDK4-selective inhibitor from BeOne Medicines (formerly BeiGene) for HR+/HER2- breast cancer; phase 1 data with letrozole showed 58-68% response rates and low hematologic toxicity, and phase 3 KANDELA-302 is underway.

BGM0504

BGM0504 is BrightGene's investigational once-weekly injectable dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes, with phase 3 weight loss of 19.3% and an NDA accepted in China in June 2026.

BGR-34

BGR-34 (NBRMAP-DB) is an Ayurvedic six-herb tablet for type 2 diabetes developed by CSIR-CIMAP and CSIR-NBRI, licensed to AIMIL Pharmaceuticals, sold in India since 2015 amid disputed clinical evidence.